Sigyn Therapeutics (SIGY) Raw Materials (2016 - 2020)

Sigyn Therapeutics has disclosed Raw Materials across 5 years of filings, most recently posting $388925.0 for Q3 2020.

• In Q3 2020, Raw Materials fell 21.42% year-over-year to $388925.0; the TTM figure through Sep 2020 stood at $388925.0 (down 21.42% YoY), while the FY2019 annual figure was $390988.0, down 25.73% from the prior year.
• Raw Materials came in at $388925.0 for Q3 2020 at Sigyn Therapeutics, roughly flat from $390725.0 in the prior quarter.
• In the past five years, Raw Materials ranged from a high of $529018.0 in Q4 2017 to a low of $388925.0 in Q3 2020.
• Average Raw Materials over 5 years is $463548.4, with a median of $471511.0 recorded in 2017.
• The largest YoY upside for Raw Materials was 10.72% in 2019 against a maximum downside of 25.73% in 2019.
• Over 5 years, Raw Materials stood at $478096.0 in 2016, then climbed by 10.65% to $529018.0 in 2017, then declined by 0.48% to $526473.0 in 2018, then dropped by 25.73% to $390988.0 in 2019, then decreased by 0.53% to $388925.0 in 2020.
• Per Business Quant data, the three most recent Raw Materials figures were $388925.0 in Q3 2020, $390725.0 in Q2 2020, and $390725.0 in Q1 2020.